Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Research and practice in thrombosis and haemostasis·2026

Same author

Relationships between bleeding assessment tools (ISTH-BAT, Self-BAT) and quality of life in patients with bleeding symptoms.

Research and practice in thrombosis and haemostasis·2026

Same author

How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach.

Blood advances·2026

Same author

Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay.

Blood advances·2025

Same author

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.

The New England journal of medicine·2025

Same author

When sickle cell trait is not just trait: risk of VTE.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

D-dimer antigen: current concepts and future prospects.

Soheir S Adam¹, Nigel S Key, Charles S Greenberg

¹University of North Carolina, Chapel Hill, NC 27599-7305, USA. soheir_adam@med.unc.edu

|November 15, 2008

Summary

This summary is machine-generated.

D-dimer, a fibrin degradation marker, forms through thrombin, factor XIIIa, and plasmin action. Its measurement aids in excluding venous thromboembolism (VTE) and shows potential in other coagulation activation scenarios.

More Related Videos

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Related Experiment Videos

Last Updated: Jun 28, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Area of Science:

Biochemistry
Hematology
Clinical Diagnostics

Background:

D-dimer antigen is a specific marker of fibrin degradation.
Its formation involves sequential enzymatic actions: thrombin, factor XIIIa, and plasmin.
D-dimer can arise from soluble fibrin or degraded fibrin clots.

Purpose of the Study:

To discuss the dynamics of D-dimer antigen formation.
To provide an overview of commercially available D-dimer assays.
To review the clinical utility of D-dimer measurement in venous thromboembolism (VTE) and other coagulation activation settings.

Main Methods:

Review of enzymatic pathways involved in fibrinolysis.
Overview of existing D-dimer assay technologies.
Synthesis of clinical evidence regarding D-dimer's diagnostic utility.

Main Results:

Detailed explanation of the sequential enzymatic process leading to D-dimer formation.
Categorization and description of various commercial D-dimer assays.
Evidence supporting D-dimer's established role in VTE exclusion.

Conclusions:

D-dimer formation is a complex process involving key hemostatic enzymes.
D-dimer assays are valuable diagnostic tools, particularly for VTE.
Emerging applications of D-dimer as a marker for coagulation activation are under investigation.